Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback